Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation
Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with somatic mutation (L265P) of myeloid differentiation primary response 88 gene (MYD88) in 80-90%, or various mutations of C-terminal domain of the C-X-C chemokine receptor type 4 (CXCR4) gene in 20-40% of cases. A unique, progressive case of concurrent MDS and WM with several somatic mutations (some unreported before) and a novel balanced reciprocal translocation between chromosomes 10 and 13 is presented below.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Current oncology (Toronto, Ont.) - 29(2022), 7 vom: 29. Juni, Seite 4587-4592 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
DeRosa, Peter A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Completed 27.07.2022 Date Revised 08.09.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/curroncol29070363 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34397116X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34397116X | ||
| 003 | DE-627 | ||
| 005 | 20231226021700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/curroncol29070363 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM34397116X | ||
| 035 | |a (NLM)35877223 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a DeRosa, Peter A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2022 | ||
| 500 | |a Date Revised 08.09.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Myelodysplastic syndromes (MDS) and Waldenstrom's macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with somatic mutation (L265P) of myeloid differentiation primary response 88 gene (MYD88) in 80-90%, or various mutations of C-terminal domain of the C-X-C chemokine receptor type 4 (CXCR4) gene in 20-40% of cases. A unique, progressive case of concurrent MDS and WM with several somatic mutations (some unreported before) and a novel balanced reciprocal translocation between chromosomes 10 and 13 is presented below | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a cytogenetics | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a hematology/oncology | |
| 650 | 4 | |a lymphoma | |
| 650 | 4 | |a myelodysplastic syndrome | |
| 650 | 4 | |a pathology | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Myeloid Differentiation Factor 88 |2 NLM | |
| 700 | 1 | |a Roche, Kyle C |e verfasserin |4 aut | |
| 700 | 1 | |a Nava, Victor E |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sunita |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Min-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Anita |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology (Toronto, Ont.) |d 1998 |g 29(2022), 7 vom: 29. Juni, Seite 4587-4592 |w (DE-627)NLM09444482X |x 1718-7729 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:7 |g day:29 |g month:06 |g pages:4587-4592 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/curroncol29070363 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 7 |b 29 |c 06 |h 4587-4592 | ||